NCT03668951View on ClinicalTrials.gov

Pharmacokinetic Study of Dexmedetomidine After Intra-Nasal and Buccal Dosing in Children

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 20, 2018

Primary Completion Date

May 3, 2022

Study Completion Date

May 3, 2022

Conditions
Heart Diseases
Interventions
DRUG

Dexmedetomidine buccal

DEX 2 mcg/kg buccal

DRUG

Dexmedetomidine Intranasal

DEX 3 mcg/kg intranasal

DRUG

Dexmedetomidine Intranasal

DEX 4 mcg/kg intranasal

Trial Locations (1)

45229

Joanna Paquin, Cincinnati

All Listed Sponsors
lead

Children's Hospital Medical Center, Cincinnati

OTHER

NCT03668951 - Pharmacokinetic Study of Dexmedetomidine After Intra-Nasal and Buccal Dosing in Children | Biotech Hunter | Biotech Hunter